A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Active, not recruiting · Phase 3 · NCT06230224
Conditions: B-Cell Non-Hodgkin Lymphoma (B-NHL)
At a glance
- Research payments reported, 2025
- $3,740
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 216
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Odronextamab (drug), Ifosfamide (drug), Carboplatin (drug), Etoposide (drug), Rituximab (drug), Dexamethasone (drug), Cisplatin (drug), Cytarabine (drug), Gemcitabine (drug)
- Dates
- Started 2024-02-15; completion 2029-05-29
- Results posted
- Not yet
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug versus Standard of Care (SOC) * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which cou…
From ClinicalTrials.gov, last updated 2026-05-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $3,740 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $3,740
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.